Aragon Pharmaceuticals, Inc.

This study offers apalutamide to men whose prostate cancer has stopped responding to hormone therapy but has not yet spread. The goal is to collect safety information until the drug becomes widely available. Participants must have rising PSA levels and continue their current horm…

This study looked at how two drugs, JNJ-56021927 and abiraterone acetate, interact in men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to check safety and find the right doses. Fifty-seven men took part, and the results help doctors under…

This study tested whether adding apalutamide to standard treatment (abiraterone and prednisone) can slow the growth of metastatic prostate cancer that no longer responds to hormone therapy. About 982 men who had not yet received chemotherapy took part. The goal was to see if the …

This study tested a drug called apalutamide in over 1,200 men with a type of prostate cancer that has stopped responding to hormone therapy but has not yet spread. The goal was to see if the drug could delay the cancer from spreading to bones or other organs. Participants receive…

This study tests whether adding apalutamide to standard hormone therapy can delay cancer spread in men with high-risk prostate cancer who are also receiving radiation therapy. About 1,500 participants took either the drug combination or a placebo. The main goal is to see if the t…

This study tested whether adding the drug apalutamide to standard hormone therapy (ADT) helps men with prostate cancer that has spread to other parts of the body. Over 1,000 participants were randomly assigned to receive either apalutamide plus ADT or a placebo plus ADT. The goal…

This study looks at how the experimental drug JNJ-56021927 changes the way the body processes other common medications in men with castration-resistant prostate cancer. About 23 participants will take the study drug along with a cocktail of other drugs to measure how their levels…